ClinicalTrials.gg
CompletedNCT00489424Updated Feb 18, 2011Results posted

Acetaminophen or Fluvastatin Compared to Placebo on the Transient Post-Dose Symptoms (PDS) Following an Intravenous (i.v.) Infusion of a Single Dose of Zoledronic Acid 5mg, in Post-menopausal Women With Low Bone Mass

A Phase 4 interventional study of Placebo and Acetaminophen in Osteoporosis, sponsored by Novartis Pharmaceuticals. Completed at 1 site in United States. Open to female participants aged 45 Years to 79 Years. Per ClinicalTrials.gov, last updated 2011-02-18.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
793
Allocation
Randomized
Ages
45 Years to 79 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 30 studies in Osteoporosis by Novartis — none open to participants now, none under way, none of them phase 3. Osteoporosis · Novartis.

Enrollment
6th of 29
793 · median 190
Started
2007
with 1 other
Phase 4
4 of 30
none open now
Registered
21st of 30
by date

Among the 30 studies in Osteoporosis by Novartis, this one is the 6th largest by enrollment of the 29 interventional ones that give a count, is one of 2 that started in 2007, is one of 4 in phase 4, and was the 21st registered.

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.

Browse Osteoporosis studies →

Open to participants now

None of the 30 studies in Osteoporosis by Novartis is open now. The open studies under Osteoporosis, anywhere →

Who these studies take

Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.

This study: 45 Years to 79 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 30 studies in Osteoporosis by Novartis as a file.
02

Study summary

This study will evaluate the efficacy of acetaminophen or fluvastatin in reducing the rate of occurrence and the severity of post dose symptoms that may occur during the 3 day period following a zoledronic acid infusion in post menopausal women with low bone mass.

03

Conditions studied

  • Osteoporosis

Browse trials for

Keywords

  • zoledronic acid
  • post dose symptoms
  • transient
  • acetaminophen
  • fluvastatin
04

Who can participate

Ages eligible
45 Years to 79 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. women greater than or equal to 45 and less than or equal to 79 years of age at randomization
  2. Women who are clinically indicated for treatment with Bisphosphonates for osteopenia or osteoporosis with a documented central (spine or hip) Bone Mineral Density T Score less than or equal to 1.5

Exclusion criteria

Exclusion Criteria:

  1. Any prior treatment with intravenous Bisphosphonates
  2. Oral treatment with Bisphosphonates for more than 8 weeks or within 6 months prior to the screening visit
  3. Patients who are taking, and are unwilling or unable to stop taking, certain medications
  4. Patients who require anticoagulant therapy
  5. Patients with a known to ibuprofen, ACET, bisphosphonates, statins or with allergies manifested by attacks of asthma, urticaria or acute rhinitis following
  6. Proteinuria (protein detected on a urine dipstick) greater than or equal to 2+ at screening
  7. Protocol specific laboratory values that fall out of range for this study
  8. Ongoing infection (oral body temperature greater than or equal to 37.5C (99.5°F),chronic febrile disease or fever of unknown origin at screening or randomization
  9. Active dental infection, unhealed dental extraction or planned oral surgery within 3 months after randomization
  10. History of iritis, uveitis or chronic conjunctivitis
  11. History of hypoparathyroidism, hyperparathyroidism or Paget's Disease
  12. Partial or total removal of parathyroid or thyroid gland
  13. History of of any organ system, treated or untreated, within the past 1 year whether or not there is evidence of local recurrence or , with the exception of localized basal cell carcinoma of the skin
  14. Treatment with an drug within the previous 30 days of screening
  15. Patients with any medical or psychiatric condition which, in the opinion of the Principal Investigator, would preclude the participant from adhering to the protocol or completing the trial per protocol, or any patient who the Principal Investigator thinks should not participate in the study for any reason, including current drug or alcohol abuse

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
793 participants (actual)

Study arms

  • Experimental
    Acetaminophen

    2 capsules of acetaminophen 325 mg and 2 capsules of placebo (matching fluvastatin) administered 45 +/- 15 minutes prior to i.v. infusion of zoledronic acid 5 mg, then 2 capsules of acetaminophen 325 mg 4 times per day (including medication taken at study site at visit 2/day 1) over the next 3 days (not exceeding 8 capsules in a 24-hour period).

    Drug: Acetaminophen

  • Experimental
    Fluvastatin

    2 capsules of fluvastatin 40 mg and 2 capsules of placebo (matching acetaminophen) administered 45 +/- 15 minutes prior to i.v. infusion of zoledronic acid 5 mg, then 2 capsules of placebo (matching acetaminophen) 4 times per day (including medication taken at study site at visit 2/day 1) over the next 3 days (not exceeding 8 capsules in a 24-hour period).

    Drug: Fluvastatin

  • Placebo comparator
    Placebo

    2 capsules of placebo (matching fluvastatin) and 2 capsules of placebo (matching acetaminophen) administered 45 +/- 15 minutes prior to intravenous (i.v.) infusion of zoledronic acid 5 mg, then 2 capsules of placebo (matching acetaminophen) 4 times per day (including medication taken at study site at visit 2/day 1) over the next 3 days (not exceeding 8 capsules in a 24-hour period).

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of Patients With a Clinically Significant Increase in Oral Body Temperature or Use of Rescue Medication.

    Clinically significant increase in oral body temperature or used rescue medication ibuprofen \>= 1 time during the 3-day period after i.v. infusion of zoledronic acid 5 mg. A clinically significant increase in body temperature was defined as an increase of at least 1 degree Celsius from baseline and a mean oral body temperature reading of at least 38.5 degrees Celsius occurring at least once during the 3-day treatment period.

    Time frame: 0 - 3 days

Secondary outcomes

  1. Proportion of Patients With a Clinically Significant Increase in Oral Body Temperature.

    Clinically significant increase in oral body temperature \>= 1 time during the 3-day period after i.v. infusion of zoledronic acid 5 mg. A clinically significant increase in body temperature was defined as an increase of at least 1 degree Celsius from baseline and a mean oral body temperature reading of at least 38.5 degrees Celsius occurring at least once during the 3-day treatment period.

    Time frame: 0 - 3 days

  2. Proportion of Patients Who Used Rescue Medication.

    Patients that took rescue medication \>= 1 time during the 3-day period after i.v. infusion of zoledronic acid 5 mg. Patients who experienced severe discomfort after their first home measurements and self-administration of study medication were allowed to take ibuprofen (200 mg tablets every 4-6 hours as needed) as rescue medication while continuing to take their study medication.

    Time frame: 0 - 3 days

  3. Number of Rescue Medication Tablets Taken

    Patients who experienced severe discomfort after their first home measurements and self-administration of study medication were allowed to take ibuprofen (200 mg tablets every 4-6 hours as needed) as rescue medication while continuing to take their study medication.

    Time frame: 0 - 3 days

  4. Time to First Rescue Medication After Infusion of Zoledronic Acid 5 mg.

    Patients who experienced severe discomfort after their first home measurements and self-administration of study medication were allowed to take ibuprofen (200 mg tablets every 4-6 hours as needed) as rescue medication while continuing to take their study medication.

    Time frame: 0 - 3 days

  5. Proportion of Patients With a Major Increase (Worsening) in Severity of Questionnaire Symptoms.

    A major increase (worsening) in severity was defined as an increase in severity of 2 units or more from baseline at least once during the 3 days immediately following i.v. infusion of zoledronic acid 5 mg. The severity of the symptom was evaluated using a 4-point categorical scale (0 = absent, 1 = mild, 2 = moderate, 3 = severe).

    Time frame: 0 - 3 days

  6. Proportion of Patients Reporting Severe Questionnaire Symptoms.

    A severe questionnaire symptom was defined as experiencing a severe specified symptom (feeling feverish, experiencing headaches, having aches and pains of muscles and joints) at least once post-baseline.

    Time frame: 0 - 3 days

  7. Change From Baseline in Visual Analog Scale (VAS) Measurement of Symptom Severity

    Effect on severity of symptoms following i.v. infusion of zoledronic acid 5 mg. The VAS is a 100-mm linear visual analog scale (0 = no symptoms to 100 = severe symptoms). The baseline VAS measurement was defined as the VAS measurement recorded prior to the infusion.

    Time frame: 0 - 3 days

07

Results

Posted Sep 14, 2009

Participant flow

Participant flow — Overall Study
MilestonePlaceboAcetaminophenFluvastatin
Started267264262
Completed263259257
Not completed455
Withdrew: Adverse event334
Withdrew: Lack of efficacy100
Withdrew: Administrative problems021

Outcome measures

PrimaryProportion of Patients With a Clinically Significant Increase in Oral Body Temperature or Use of Rescue Medication.

Clinically significant increase in oral body temperature or used rescue medication ibuprofen \>= 1 time during the 3-day period after i.v. infusion of zoledronic acid 5 mg. A clinically significant increase in body temperature was defined as an increase of at least 1 degree Celsius from baseline and a mean oral body temperature reading of at least 38.5 degrees Celsius occurring at least once during the 3-day treatment period.

Time frame:
0 - 3 days
Reported as:
Number · proportion of patients
Proportion of Patients With a Clinically Significant Increase in Oral Body Temperature or Use of Rescue Medication.
proportion of patientsPlaceboAcetaminophenFluvastatin
Increase in oral body temperature:Yes0.6070.3980.618
Increase in oral body temperature:No0.390.6020.382
SecondaryProportion of Patients With a Clinically Significant Increase in Oral Body Temperature.

Clinically significant increase in oral body temperature \>= 1 time during the 3-day period after i.v. infusion of zoledronic acid 5 mg. A clinically significant increase in body temperature was defined as an increase of at least 1 degree Celsius from baseline and a mean oral body temperature reading of at least 38.5 degrees Celsius occurring at least once during the 3-day treatment period.

Time frame:
0 - 3 days
Reported as:
Number · proportion of patients
Proportion of Patients With a Clinically Significant Increase in Oral Body Temperature.
proportion of patientsPlaceboAcetaminophenFluvastatin
Increase in oral body temperature: Yes0.1050.0490.115
Increase in oral body temperature: No0.8910.9510.885
SecondaryProportion of Patients Who Used Rescue Medication.

Patients that took rescue medication \>= 1 time during the 3-day period after i.v. infusion of zoledronic acid 5 mg. Patients who experienced severe discomfort after their first home measurements and self-administration of study medication were allowed to take ibuprofen (200 mg tablets every 4-6 hours as needed) as rescue medication while continuing to take their study medication.

Time frame:
0 - 3 days
Reported as:
Number · proportion of patients
Proportion of Patients Who Used Rescue Medication.
proportion of patientsPlaceboAcetaminophenFluvastatin
Took rescue medication >= 1 time: Yes0.5730.3860.595
Took rescue medication >= 1 time: No0.4230.6140.405
SecondaryNumber of Rescue Medication Tablets Taken

Patients who experienced severe discomfort after their first home measurements and self-administration of study medication were allowed to take ibuprofen (200 mg tablets every 4-6 hours as needed) as rescue medication while continuing to take their study medication.

Time frame:
0 - 3 days
Reported as:
Mean · tablets
Number of Rescue Medication Tablets Taken
tabletsPlaceboAcetaminophenFluvastatin
Number of Rescue Medication Tablets Taken6.3 ± 4.415.7 ± 4.736.5 ± 4.78
SecondaryTime to First Rescue Medication After Infusion of Zoledronic Acid 5 mg.

Patients who experienced severe discomfort after their first home measurements and self-administration of study medication were allowed to take ibuprofen (200 mg tablets every 4-6 hours as needed) as rescue medication while continuing to take their study medication.

Time frame:
0 - 3 days
Reported as:
Mean · hours
Time to First Rescue Medication After Infusion of Zoledronic Acid 5 mg.
hoursPlaceboAcetaminophenFluvastatin
Time to First Rescue Medication After Infusion of Zoledronic Acid 5 mg.21.9 ± 12.2128.2 ± 18.1519.9 ± 40.95
SecondaryProportion of Patients With a Major Increase (Worsening) in Severity of Questionnaire Symptoms.

A major increase (worsening) in severity was defined as an increase in severity of 2 units or more from baseline at least once during the 3 days immediately following i.v. infusion of zoledronic acid 5 mg. The severity of the symptom was evaluated using a 4-point categorical scale (0 = absent, 1 = mild, 2 = moderate, 3 = severe).

Time frame:
0 - 3 days
Reported as:
Number · proportion of patients
Proportion of Patients With a Major Increase (Worsening) in Severity of Questionnaire Symptoms.
proportion of patientsPlaceboAcetaminophenFluvastatin
Feeling feverish0.3950.2350.397
Headache0.3910.2540.439
Aches and pains of muscles/joints0.4770.3370.462
SecondaryProportion of Patients Reporting Severe Questionnaire Symptoms.

A severe questionnaire symptom was defined as experiencing a severe specified symptom (feeling feverish, experiencing headaches, having aches and pains of muscles and joints) at least once post-baseline.

Time frame:
0 - 3 days
Reported as:
Number · proportion of patients
Proportion of Patients Reporting Severe Questionnaire Symptoms.
proportion of patientsPlaceboAcetaminophenFluvastatin
Feeling feverish0.1350.0760.145
Headache0.1570.0680.160
Aches and pains of muscles/joints0.3030.2120.302
SecondaryChange From Baseline in Visual Analog Scale (VAS) Measurement of Symptom Severity

Effect on severity of symptoms following i.v. infusion of zoledronic acid 5 mg. The VAS is a 100-mm linear visual analog scale (0 = no symptoms to 100 = severe symptoms). The baseline VAS measurement was defined as the VAS measurement recorded prior to the infusion.

Time frame:
0 - 3 days
Reported as:
Mean · units on a scale
Change From Baseline in Visual Analog Scale (VAS) Measurement of Symptom Severity
units on a scalePlaceboAcetaminophenFluvastatin
Change from baseline to Day 1 - late evening7.6 ± 22.744.4 ± 18.006.0 ± 18.89
Change from baseline to Day 2 - late evening18.9 ± 25.8611.8 ± 23.2220.8 ± 27.18
Change from baseline to Day 3 - late evening6.2 ± 19.663.9 ± 17.596.6 ± 20.40

Adverse events

Collected over At the end of study. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—1/267 (0.4%)34/267 (12.7%)
Acetaminophen—2/264 (0.8%)39/264 (14.8%)
Fluvastatin—2/262 (0.8%)36/262 (13.7%)
Most frequent serious events
Most frequent serious events
EventPlaceboAcetaminophenFluvastatin
UveitisEye disorders0/2670/2641/262
PyrexiaGeneral disorders0/2670/2641/262
ConvulsionNervous system disorders0/2670/2641/262
SyncopeNervous system disorders0/2671/2640/262
Pleuritic painRespiratory, thoracic and mediastinal disorders0/2671/2640/262
HypokalaemiaMetabolism and nutrition disorders1/2670/2640/262
Most frequent other events
Most frequent other events
EventPlaceboAcetaminophenFluvastatin
NauseaGastrointestinal disorders7/26716/2648/262
HeadacheNervous system disorders8/26714/26415/262
ArthralgiaMusculoskeletal and connective tissue disorders13/2679/26414/262
MyalgiaMusculoskeletal and connective tissue disorders14/26711/26410/262

Baseline characteristics

Age, Customized
Age, Customized(participants)PlaceboAcetaminophenFluvastatinTotal
Between 45 and 55 years646967200
Between 56 and 64 years1029892292
>=65 years10197103301
Sex/Gender, Customized
Sex/Gender, Customized(participants)PlaceboAcetaminophenFluvastatinTotal
Female267264262793
08

Study locations

1 site
  • Refer to the E-portal link for ZOL446HUS136
    Http://www.osteoporosisclinicalresearch.com, New Jersey, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2007, a primary completion of Dec 2007 and a completion of Dec 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2009, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2007
First posted
Jun 21, 2007
Start
Jun 2007
Primary completionActual
Dec 2007
CompletionActual
Dec 2007
Results first posted
Sep 14, 2009
Last update
Feb 18, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00489424
First posted
Jun 21, 2007
Start date
Jun 2007
Primary completion
Dec 2007
Completion
Dec 2007
Results posted
Sep 14, 2009
Last update
Feb 18, 2011

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Acetaminophen · Fluvastatin

Start the discussion